Trimethoprim/Sulfamethoxazole

Phase 3Small molecule

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Trimethoprim/Sulfamethoxazole is one of 61 small molecule programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseRecruiting

Posterior Urethral ValveRecruiting

Rheumatic DiseasePhase 3

Recruiting

Posterior Urethral ValvePhase 3

Recruiting

Competition

Competitive Landscape

63 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Voltaren

Aleve

Advil

Decadron

AAspen Global Incorporated

Approved

—5

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—6

Ansaid

PPharmacia and Upjohn

Approved

—7

Oruvail

WWyeth-Lederle Vaccines

Zovirax

Celebrex

PPhiladelphia Eye Associates

Approved

—10

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Posterior Urethral Valve

NCT06737016

Post-ApprovalRecruiting

Rheumatic Disease

NCT06499233

Q1 2027

Phase 2Recruiting

Eczema

NCT01631617

Clinical

Trials by Indication[1]

Antibiotic Prophylaxis2 trials

Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole

Unknown status·UUmeå University·Phase 2·NCT02734732·2,800 enrolled

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

Completed·UUniversity of California, San Diego·N/A·NCT02944825·80 enrolled

Abscess2 trials

Antibiotic Therapy After Incision and Drainage for Abscess

Withdrawn·WWake Forest University·N/A·NCT00900510

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

Completed·—·Phase 3·NCT00691600·23 enrolled

Urinary Tract Infection2 trials

Probiotics for Girls With Recurring Urinary Tract Infections

Withdrawn·—·Phase 2·NCT00789464

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01595529·717 enrolled

Prophylaxis2 trials

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

Completed·RRadboud University Medical Center·Phase 4·NCT03228108·1,538 enrolled

Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT01747278·80 enrolled

Liver abscess1 trial

Antibiotics for Klebsiella Liver Abscess Study

Completed·NNational University Hospital, Singapore·Phase 4·NCT01723150·152 enrolled

10 more indications

Completed·JJohns Hopkins University·Phase 2·NCT01594827·29 enrolled

Posterior Urethral Valve1 trial

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

Recruiting·MMansoura University·Phase 3·NCT06737016·50 enrolled

Plasmodium Falciparum1 trial

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 1/2·NCT01632891·52 enrolled

Congenital Abnormalities1 trial

Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract

Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 3·NCT02021006·292 enrolled

Islet Transplantation1 trial

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

No longer available·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT01049633

Cystic Fibrosis1 trial

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01349192·47 enrolled

Rheumatic Disease1 trial

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

Recruiting·TTongji Hospital·Phase 4·NCT06499233·800 enrolled

Eczema1 trial

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Recruiting·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT01631617·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Trimethoprim/Sulfamethoxazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trimethoprim/Sulfamethoxazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trimethoprim/Sulfamethoxazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Trimethoprim/Sulfamethoxazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Antibiotic Prophylaxis2 trials

Abscess2 trials

Urinary Tract Infection2 trials

Prophylaxis2 trials

Liver abscess1 trial

Recurrent urinary tract infections1 trial

Tuberculosis1 trial

Staphylococcus Aureus1 trial

Posterior Urethral Valve1 trial

Plasmodium Falciparum1 trial

Congenital Abnormalities1 trial

Islet Transplantation1 trial

Cystic Fibrosis1 trial

Rheumatic Disease1 trial

Eczema1 trial

References

Drug Info

Quick Facts

Related News